Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

1988
2025

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 1
1992 1
1997 1
1999 1
2001 1
2002 2
2009 1
2010 2
2011 1
2012 2
2013 3
2014 3
2015 3
2016 3
2017 2
2018 2
2019 4
2020 4
2021 1
2022 1
2023 1
2024 3
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Inhibition of CD40L with Frexalimab in Multiple Sclerosis.
Vermersch P, Granziera C, Mao-Draayer Y, Cutter G, Kalbus O, Staikov I, Dufek M, Saubadu S, Bejuit R, Truffinet P, Djukic B, Wallstroem E, Giovannoni G; Frexalimab Phase 2 Trial Group. Vermersch P, et al. Among authors: truffinet p. N Engl J Med. 2024 Feb 15;390(7):589-600. doi: 10.1056/NEJMoa2309439. N Engl J Med. 2024. PMID: 38354138 Clinical Trial.
Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide.
Tornatore C, Wiendl H, Lublin AL, Geertsen SS, Chavin J, Truffinet P, Bar-Or A. Tornatore C, et al. Among authors: truffinet p. Front Neurol. 2022 Feb 28;13:828616. doi: 10.3389/fneur.2022.828616. eCollection 2022. Front Neurol. 2022. PMID: 35295832 Free PMC article. Review.
Biomarqueurs aux phases précoces de développement dans la maladie d'Alzheimer.
Bordet R, Dartigues JF, Dubois B, Goehrs JM, Vernoux L, Semah F, Pasquier F, Bidaut-Mazel C; les participants à la Table Ronde n°3 de Giens XXV. Bordet R, et al. Therapie. 2010 Jul-Aug;65(4):277-83. doi: 10.2515/therapie/2010039. Therapie. 2010. PMID: 27393108 French. No abstract available.
Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial.
Kuhle J, Chitnis T, Banwell B, Tardieu M, Arnold DL, Rawlings AM, Geertsen SS, Lublin AL, Saubadu S, Truffinet P, Kappos L. Kuhle J, et al. Among authors: truffinet p. Mult Scler. 2023 Mar;29(3):385-394. doi: 10.1177/13524585221144742. Epub 2023 Jan 12. Mult Scler. 2023. PMID: 36632983 Free PMC article. Clinical Trial.
Randomized trial of oral teriflunomide for relapsing multiple sclerosis.
O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, Freedman MS; TEMSO Trial Group. O'Connor P, et al. Among authors: truffinet p. N Engl J Med. 2011 Oct 6;365(14):1293-303. doi: 10.1056/NEJMoa1014656. N Engl J Med. 2011. PMID: 21991951 Free article. Clinical Trial.
Biomarkers for the early stages of clinical development in Alzheimer's disease.
Bordet R, Dartigues JF, Dubois B, Goehrs JM, Vernoux L, Semah F, Pasquier F, Bidaut-Mazel C; participatnts of Round Table n°3 if Giens XXV. Bordet R, et al. Therapie. 2010 Jul-Aug;65(4):285-90, 277-283. doi: 10.2515/therapie/2010040. Epub 2010 Sep 21. Therapie. 2010. PMID: 20854749 Review. English, French.
Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial.
Chitnis T, Banwell B, Kappos L, Arnold DL, Gücüyener K, Deiva K, Skripchenko N, Cui LY, Saubadu S, Hu W, Benamor M, Le-Halpere A, Truffinet P, Tardieu M; TERIKIDS Investigators. Chitnis T, et al. Among authors: truffinet p. Lancet Neurol. 2021 Dec;20(12):1001-1011. doi: 10.1016/S1474-4422(21)00364-1. Lancet Neurol. 2021. PMID: 34800398 Clinical Trial.
38 results